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Abstract
Background: Triple-negative breast cancer (TNBC) is the most aggressive and invasive of the breast cancer
subtypes. TNBC is a challenging disease that lacks targets for treatment. Histone deacetylase inhibitors (HDACi) are a
group of targeted anticancer agents that enhance radiosensitivity. Bcl-2/adenovirus E1B 19 kDa protein-interacting
protein 3 (BNIP3) is a member of the Bcl-2 subfamily. BNIP3 is not found in normal breast tissue but is up-regulated
in breast cancer. In the present study, we investigated the anti-cancer effects of a newly developed HDACi, YCW1,
combined with ionizing radiation (IR) in TNBC in vitro and in an orthotopic mouse model. Furthermore, we
examined the relationship between autophagy and BNIP3.
Methods: Trypan blue exclusion was used to investigate the viability of 4 T1 (a mouse TNBC cell line) and
MDA-MB-231 cells (a human TNBC cell line) following combined YCW1 and IR treatment. Flow cytometry was used
to determine apoptosis and autophagy. The expression levels of BNIP3, endoplasmic reticulum (ER) stress- and
autophagic-related proteins were measured using western blot analysis. An orthotopic mouse model was used to
investigate the in vivo effects of YCW1 and IR alone and in combination. Tumor volumes were monitored using a
bioluminescence-based IVIS Imaging System 200.
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Results: We found that YCW1 significantly enhanced toxicity in 4 T1 cells compared with suberoylanilide
hydroxamic acid (SAHA), which was the first HDACi approved by the Food and Drug Administration for clinical use
in cancer patients. The combined treatment of YCW1 and IR enhanced cytotoxicity by inducing ER stress and
increasing autophagy induction. Additionally, the combined treatment caused autophagic flux and autophagic cell
death. Furthermore, the expression level of BNIP3 was significantly decreased in cells following combined
treatment. The downregulation of BNIP3 led to a significant increase in autophagy and cytotoxicity. The combined
anti-tumor effects of YCW1 and IR were also observed in an orthotopic mouse model; combination therapy
resulted in a significant increase in autophagy and decreased tumor tissue expression of BNIP3 in the tumor tissue.
Conclusions: These data support the possibility of using a combination of HDACi and IR in the treatment of TNBC.
Moreover, BNIP3 may be a potential target protein for TNBC treatment.
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Background
Triple-negative breast cancer (TNBC) characterized by
the absence of estrogen receptor alpha (ER), progester-
one receptor (PR) and human epidermal growth factor
receptor 2 (HER2) expression, is a basal-like subgroup of
breast cancers that accounts for 10–20 % of all breast
cancers [1]. Patients with this subtype are more likely to
develop recurrence within the first 5 years, and survival
following metastatic relapse is shorter for TNBC patients
than those with other breast cancer subtypes [2]. Cur-
rently, TNBC is one of the most attractive areas in can-
cer research. One reason for this scientific interest is the
lack of therapeutic targets for TNBC. Therefore, identi-
fying biological markers of TNBC progression could be
helpful for the prevention of breast cancer metastasis
and could provide novel therapeutic strategies for the
disease. TNBC is typically treated with surgery, radio-
therapy, and chemotherapy. Overcoming the deleterious
consequences of radiotherapy and maximizing its anti-
tumor effects to control tumor progression should be
the goal of combined radio- and chemotherapy. Com-
bination therapies aim to enhance radiosensitivity and
prevent tumor recurrence. Numerous conventional cyto-
toxic drugs are used in conjunction with different radi-
ation techniques [3]. Recently, data accumulated by us
and others have revealed that some compounds or drugs
enhanced radiosensitivity through regulation of the cell
cycle, induction of cell death and inhibition of DNA re-
pair [1, 4–6].
Ionizing radiation (IR) induces important signal trans-
duction pathways, such as the PI3K pathway, that are
linked with radioprotective and growth-promoting
events [7]. The PI3K signaling pathway is associated with
major radioresistance mechanisms, such as intrinsic ra-
diosensitivity, tumor cell proliferation and hypoxia [8].
Downstream molecular targets of PI3K up-regulate
hypoxia-related proteins, stimulate mitogenic and pro-
survival pathways and have anti-apoptotic effects via the
induction of Bcl-XL, which is a member of the Bcl-2
family, and the inactivation of Bad and procaspase-9 [9].
Positive Bcl-2 expression has been associated with poor
survival and reduced sensitivity to chemotherapy in pa-
tients with TNBC [10]. Bcl-2/adenovirus E1B 19 kDa
protein-interacting protein 3 (BNIP3) is a member of
the Bcl-2 subfamily of death-inducing mitochondrial
proteins [11]. Previous studies have demonstrated that
BNIP3 provides a survival advantage in cancer cells by
promoting autophagy and eliminating damaged mito-
chondria with low membrane potential that are a source
of intracellular ROS [12, 13]. Additionally, BNIP3 ex-
pression is restricted to few normal tissues, including
skeletal muscle and brain [14]. In contrast to normal
breast tissue in which BNIP3 was not expressed up-
regulation of BNIP3 was observed in breast cancer [15].
However, whether BNIP3 has an important role in
TBNC remains unknown.
Many studies have implicated that HDAC enzymes
have a role in the development of cancer and, therefore,
are potential therapeutic targets [16, 17]. HDAC inhibi-
tors (HDACi) block the deacetylation function of
HDACs, causing cell cycle arrest, endoplasmic reticulum
(ER) stress, differentiation, inhibition of angiogenesis,
apoptosis and autophagy in many tumors [6, 17]. Nor-
mal cells are relatively resistant to HDACi-induced cell
death [18]. Moreover, HDACi can affect apoptosis and
autophagy through regulation of the Bcl-2 family includ-
ing inhibition of Bcl-2 and activation of Bax [19]. How-
ever, several serious adverse events were reported in
patients treated with suberoylanilide hydroxamic acid
(SAHA), which was the first HDACi approved by the US
Food and Drug Administration (FDA) for the clinical
treatment of cutaneous T-cell lymphoma, and other
HDACi [20]. Therefore, the development of novel
HDACi combination therapies or new HDACi with im-
proved efficacies is urgently needed, particularly for solid
tumors.
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In this study, we used a newly developed HDACi,
YCW1 (octanedioic acid [3-(2-(5-methoxy-1H-indol-1-
yl)ethoxy)phenyl]-amide N-hydroxyamide), which was
been optimized for HDAC inhibition using structure-
based analyses [21, 22]. The murine TNBC cell line 4 T1
and human TNBC cell line MDA-MB-231 were used to
investigate the anti-tumor effects of IR combined with
this novel HDACi (YCW1) and the underlying mechan-
ism of these effects, including the types of cell death and
ER stress. Furthermore, we tested the inhibitory effect of
IR combined with YCW1 in a 4 T1 orthotopic breast
cancer model in mice. Our results suggest that the
downregulation of BNIP3 in TNBC cells significantly in-
creased the anti-tumor effects of IR and YCW1 through
the induction of autophagic cell death. Using an orthoto-
pic breast cancer mouse model of TNBC cells, we veri-
fied that co-treatment with IR and YCW1 inhibited
tumor growth.
Results
YCW1 inhibits HDAC activity and enhances cytotoxicity of
IR in TNBC cells
SAHA was the first HDACi to be approved by the FDA
for clinical use in cancer patients. However, some ser-
ious adverse events were reported in patients treated
with SAHA [23]. Therefore, we investigated the use of a
novel HDACi (YCW1). Our previous study indicated
that YCW1 is a class I and II HDACi. Furthermore,
compared with SAHA, YCW1 showed better inhibition
of total HDAC activity [22]. In the present study, we
found that YCW1 significantly enhanced toxicity in 4 T1
cells compared with SAHA in 4 T1 cells (Fig. 1a). To
further determine whether YCW1 inhibits HDAC activ-
ity in 4 T1 cells, the murine TNBC cell line was treated
with YCW1 at the indicated doses to examine the acetyl-
ation level of HDAC target proteins. YCW1 induced
dose-dependent acetylation of histones H3 and H4, and
non-histone protein tubulin (Fig. 1b). Next, we
investigated the effects of YCW1 concentration and IR
dose on 4 T1 and MDA-MB-231 cell viability (Figs. 2a
and b). YCW1 and IR treatment both decreased cell via-
bility in a concentration- and dose-dependent manner,
respectively. As shown in Fig. 2c, the combined treat-
ment with YCW1 and IR enhanced the growth inhibition
of 4 T1 and MDA-MB-231 cells compared with YCW1
or IR alone.
Combined treatment induces ER stress and autophagy in
4 T1 cells
Previous studies have demonstrated that HDACi and IR
induce ER stress [24, 25]. Therefore, we determined
whether combined treatment with YCW1 and IR induced
an ER stress response in 4 T1 cells. Our results showed
that levels of inositol-requiring enzyme 1α (IRE1α) and
eukaryotic initiation factor 2α (eIF2α) phosphorylation,
both markers of ER stress, increased in cells treated with
combined YCW1 and IR compared with those subjected
to individual treatment (Fig. 3a). Members of the Bcl-2
family act as sentinels that selectively trigger apoptosis in
response to developmental cues or stress-signals such as
ER stress [26]. We found that the Bcl-XL protein expres-
sion levels decreased in 4 T1 cells following combined
treatment. Furthermore, we analyzed the types of cell
death induced by combined treatment. Our results
showed that the occurrence of early apoptosis in 4 T1 cells
treated with YCW1 and/or IR was low (Fig. 3b). We fur-
ther analyzed the occurrence of type II programmed cell
death, autophagy. Microtubule-associated protein light
chain 3 (LC3) is widely used to monitor autophagy [27].
Thus, we applied fluorescence microscopy to determine
the percentage of cells with punctate LC3 staining (Fig. 3c).
Quantitative results showed a significant increase in LC3
immunopositive dots in 4 T1 cells that received the com-
bined treatment compared with YCW1 or IR alone. The
expression of autophagic-related LC3-II, beclin 1, p62 and
Atg5 proteins in 4 T1 cells after different treatments were
Fig. 1 Cytotoxic effects resulting from SAHA and YCW1 treatment in 4 T1 cells. a Dose-dependent effects of SAHA and YCW1 treatment on the
viability of 4 T1 cells for 24 h. *, p < 0.05, SAHA versus YCW1. Data are presented as the mean ± standard deviation of three independent experiments.
b Concentration-dependent effects of YCW1 on histone and nonhistone proteins for 24 h in 4 T1 cells
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analyzed (Fig. 3d). We found a marked increase in the ex-
pression of LC3-II, beclin 1, p62 and Atg5 proteins in
4 T1 cells treated with YCW1 and IR, alone and in com-
bination. The combined treatment showed a significant
increase in the expression of LC3-II, beclin 1 and Atg5
proteins compared with YCW1 or IR treatment alone. By
TEM, 4 T1 cells exhibited obvious autophagic vacuoles in
the cytoplasm after combined treatment (Fig. 4 and Add-
itional file 1: Figure S1B). Additionally, combined treat-
ment caused a severe dilation of ER membranes, which is
a sign of ER stress, compared with the control group.
These results confirm that the combined treatment in-
duced ER stress and autophagy in 4 T1 cells.
Autophagic cell death is induced by the combination of
YCW1 and IR
Autophagy is a cytoprotective process in starving cells.
However, excess autophagy can induce type II pro-
grammed cell death (autophagic cell death) [28]. To study
the role of autophagy in combined treatment-induced
cytotoxicity, cells were transfected with Atg5 shRNA then
exposed to YCW1and IR. Atg5 shRNA inhibited the ex-
pression of Atg5, LC3 puncta and autophagic vacuoles
(Fig. 5a, b and Additional file 1: Figure S1). Furthermore,
inhibition of autophagy by Atg5 shRNA increased the cell
viability in 4 T1 cells treated with the combined treatment
(Fig. 5c). Previous studies have suggested that one of the
criteria of autophagic cell death is an increase in autopha-
gic flux, and not just an increase in the autophagic
markers [29]. We analyzed the autophagic flux with bafilo-
mycin A1(BAF, a vacuolar-type H+-ATPase inhibitor that
blocks autophagosome-lysosome fusion). As shown in
Fig. 5c, combined treatment led to the accumulation of
LC3-II in the presence of BAF. Therefore, the increase in
LC3-II was not due to the blockade of autophagic degrad-
ation. The increase of LC3-II by BAF in cells treated with
combined treatment likely results in autophagic flux.
BNIP3 expression influences the cytotoxic effects of YCW1
and IR in 4 T1 cells
To investigate whether BNIP3 is involved in combined
treatment-induced cell death, we performed western blot-
ting to detect its protein expression levels. The results
showed that BNIP3 levels were significantly decreased in
cells treated with combined treatment compared with
those treated with YCW1 and IR alone (Fig. 6a). Next,
BNIP3 protein expression was depleted using shRNA
(Fig. 6b). We found that BNIP3 shRNA-2 inhibited more
BNIP3 expression compare with BNIP3 shRNA-1. Thus,
we used BNIP3 shRNA-2 to downregulate BNIP3 and in-
vestigated the role of BNIP3 in combined treatment-
induced cytotoxicity and autophagy. We observed that a
Fig. 2 Cytotoxic effects resulting from YCW1 and/or IR in 4 T1 and MBA-MD-231 cells. a Concentration-dependent effects of YCW1 on the viability
of 4 T1 and MBA-MD-231 cells. Cells were treated with 0.5, 1, 1.5 or 2 μM of YCW1 for 48 h. b Dose-dependent effects of IR on the viability of
4 T1 and MBA-MD-231 cells. Cells were treated with 2, 4, 6 or 8 Gy of IR for 48 h. *, p < 0.05, YCW1 or IR versus control group. c Cytotoxicity
observed in cells treated with YCW1 (1 μM) and IR (4 Gy) for 48 h in 4 T1 and MBA-MD-231 cells. #, p < 0.05, IR versus combined treatment.
*, p < 0.05, YCW1 versus combined treatment. Data are presented as the mean ± standard deviation of three independent experiments
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significant increase in LC3 immunopositive dots was ob-
served in 4 T1 cells transfected with BNIP3 shRNA com-
pared with the control shRNA (Fig. 6c). Additionally,
BNIP3 shRNA reduced the viability of 4 T1 cells (Fig. 6d).
To further confirm the role of BNIP3 in autophagy
activation, autophagy activity was measured in 4 T1 cells
expressing BNIP3. After transfection, BNIP3 expression
was significantly increased (Fig. 6e). We found that the
LC3-puncta formation showed decreased when BNIP3 is
overexpressed (Fig. 6f).
Fig. 3 Measurement of cell death and ER stress in 4 T1 cells. a The expression levels of ER stress-related proteins were measured by western blot
analysis following treatment with YCW1 and IR alone or in combination. Cells were treated with YCW1 (1 μM) and IR (4 Gy) for 12 h. b Early apoptosis,
detected using an Annexin V apoptosis detection kit, was measured using flow cytometry. Cells were treated with YCW1 (1 μM) and IR (4 Gy) for 48 h.
c Immunofluorescence staining of the LC3 protein in 4 T1 cells treated with YCW1 (1 μM) and IR (4 Gy) for 48 h. Representative cell images showing
punctate LC3 distribution using a confocal microscope. Quantitative data calculating the number of LC3 dots per cell. #, p < 0.05, IR versus combined
treatment. *, p < 0.05, YCW1 versus combined treatment. Data are presented as the mean ± standard deviation of three independent experiments. d
The expression levels of autophagic-related proteins were measured by western blot analysis following treatment with YCW1 and IR alone or in
combination. The densities of the bands were quantified with a computer densitometer (AlphaImager™ 2200 System Alpha Innotech Corporation, CA,
USA). Cells were treated with YCW1 (1 μM) and IR (4 Gy) for 48 h. #, p < 0.05, IR versus combined treatment. *, p < 0.05, YCW1 versus
combined treatment
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Tumor growth in an orthotopic breast cancer model is
suppressed by combined treatment with YCW1 and IR
through the induction of autophagy and the inhibition of
BNIP3
We next evaluated the anti-tumor growth effect of
YCW1 and IR alone, or in combination in vivo. Tumors
were induced by the injection of 4 T1-Luc cells into the
lactiferous ducts of the 4th mammary fat pads of female
Balb/c mice. We measured the body weight and tumor
volume of the mice every week. None of the treatment
regimens produced any obvious signs of toxicity based
on the loss of body weight (Fig. 7b). Furthermore, no
Fig. 4 The ultrastructures of 4 T1 cells treated with YCW1 (1 μM) and IR (4 Gy) for 48 h were analyzed by TEM. N, nucleus. Black arrows,
autophagosomes. Black arrowheads, autolysosome. White arrows, endoplasmic reticulum
Fig. 5 Measurement of autophagic and cytotoxic effects in 4 T1 cells pretreated with Atg shRNA. a Western blotting for Atg5. The cells were
transfected with Atg5 shRNA for 24 h. b Quantitative data calculating the number of LC3 dots per cell in the absence or presence of Atg5 shRNA.
c Cytotoxic effects in the absence or presence of Atg5 shRNA. Cells were transfected with Atg5 shRNA for 24 h and were then incubated with
YCW1 (1 μM) and IR (4 Gy) for 48 h. *, p < 0.05, YCW1 + IR versus Atg5 shRNA + YCW1 + IR. Data are presented as the mean ± standard deviation
of three independent experiments. d Western blot analysis of LC3-I and LC3-II expression in 4 T1 cells. Cells were pretreated with BAF for 1 h prior
to IR treatment and then treated with YCW1 (1 μM) and IR (4 Gy) for 48 h
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detectable toxicity was evident by biochemical examin-
ation following treatment with YCW1 or IR alone
(Table 1). In addition, we used an IVIS system to analyze
bioluminescence. The results showed a gradual increase
in tumor volume in the control group in a time-
dependent manner. The combined treatment suppressed
tumor volume compared with the control group (Fig. 7a
and c). Next, the expression patterns of LC3 and BNIP3
in the 4 T1 tumors were examined by IHC staining
(Fig. 7d). BNIP3 expression was decreased in the YCW1
alone, IR alone and combination groups compared with
the control group. By contrast, the expression level of
LC3 was increased. Tumor tissues from the mice treated
with both YCW1 and IR showed lower BNIP3 and
higher LC3 expression compared with the tumor tissues
from mice treated with a single agent. This experiment
showed that the combination of YCW1 and IR signifi-
cantly inhibited BNIP3 and induced autophagic cell
death in an orthotopic breast cancer model.
Discussion
TNBC is the most invasive and aggressive among the
breast cancer subtypes and there is no clinical therapy
specific for patients with TNBC [30]. In the present study,
we found that the combination of a novel HDACi
(YCW1) and IR may have anti-tumor potential against
TNBC both in vitro and in vivo (Figs. 2 and 7). Moreover,
our previous study demonstrated that YCW1 induced a
Fig. 6 BNIP3 knockdown by shRNA abrogates the growth of 4 T1 cells. a The expression levels of BNIP3 in 4 T1 cells were analyzed by western
blot analysis following YCW and/or IR treatment. Cells were treated with YCW1 (1 μM) and IR (4 Gy) for 48 h. b Transfection efficacy was verified
by western blot analysis. BNIP3 protein expression in 4 T1 cells transfected with scramble or BNIP3 shRNA for 24 h. c Quantitative data calculating
the number of LC3 dots per cell transfected with scramble or BNIP3 shRNA. *, p < 0.05. d Cytotoxicity observed in cells transfected with scramble
or BNIP3 shRNA using flow cytometry. *, p < 0.05. e Western blot analysis of BNIP3 protein expression in cells overexpressing BNIP3. f Quantitative
data calculating the number of LC3 dots in the overexpression of BNIP3. Cells were transfected with BNIP3 for 24 h and were then incubated
with YCW1 (1 μM) and IR (4 Gy) for 48 h. *, p < 0.05, YCW1 + IR versus BNIP3 + YCW1 + IR. Data are presented as the mean ± standard deviation of
three independent experiments
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Fig. 7 Combined treatment with YCW1 and IR enhances the anti-tumor effects in an orthotopic breast cancer model. a 4 T1-luc cells were
injected into the mammary fat pads of Balb/c mice, observed for luciferase signals and photographed using an IVIS 200. b Measurement of body
weight in Balb/c mice taken once per week. c Quantification of the luciferase signals. *, p < 0.05, versus control. d IHC staining of orthotopic tumor
tissues from the mice. IHC was used to determine the expression levels of LC3 and BNIP3 (×100 objective magnification). The percentage of LC3
and BNIP3-positive cells was determined using HistoQuest software (TissueGnostics)
Table 1 Biochemical tests including GOT, GPT, albumin and BUN
4 T1-Luc cells
Item/Group Normal Control YCW1 IR YCW1 + IR
GOT (U/l) 137.67 ± 42.17 147.33 ± 13.72 184.00 ± 32.32 181.67 ± 29.35 180.67 ± 18.22
GPT (U/l) 48.00 ± 10.60 35.33 ± 3.18 33.67 ± 2.67 33.33 ± 2.19 40.33 ± 7.97
Albumin (g/dl) 2.67 ± 0.13 2.37 ± 0.24 2.37 ± 0.12 2.37 ± 0.15 2.23 ± 0.13
BUN (mg/dl) 21.60 ± 2.63 30.50 ± 10.42 26.73 ± 1.07 25.47 ± 1.60 26.53 ± 1.87
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broad spectrum of anticancer activities in lung cancer cell
and animal models. It has been showed that HDACi in-
duced cell death in many tumors and had less toxicity in
normal cells [17, 18]. However, HDACi have demon-
strated limited clinical benefit for patients with solid tu-
mors [31]. In our study, we used a novel HDACi, YCW1,
and examined the combination effect of YCW1 and IR in
TNBC cells. YCW1 showed a better inhibition of total
HDAC activity and significantly enhanced toxicity com-
pared with SAHA [22] (Fig. 1a). The combined treatment
with YCW1 and IR enhanced the growth inhibition of
4 T1 and MDA-MB-231 cells compared with YCW1 or IR
alone (Fig. 2). Furthermore, YCW1 caused no detectable
toxicity as determined by either biochemical examination
or in terms of the loss of body weight (Fig. 7b and Table 1).
Therefore, YCW1 is a potential HDAC inhibitor and en-
hances radiosensitivity in TNBC cells.
HDACi cause ER stress, apoptosis and autophagy in
many tumors [6, 17]. Previous research has shown that
treatment of cancer cells with HDACi induced autoph-
agy which promotes cancer cell survival when apoptosis
induction is inhibited. Moreover, autophagy inhibition
resulted in a higher level of apoptosis in response to
SAHA treatment [32]. Rao et al. indicated that combin-
ation of autophagy inhibitor and HDACi induced the ac-
cumulation of toxic polyubiquitylated proteins and
caused inhibitory effects on TNBC cell growth [33].
However, there are also numerous reports in the litera-
ture showing the pro-death function of autophagy.
HDACi can induce caspase-independent autophagic cell
death and have clear clinical implications in treating
cancers with apoptotic defects [34, 35]. Therefore, the
role of autophagy in regulating cancer cell death or sur-
vival remains controversial. Recent studies have investi-
gated the induction of ER stress as a novel strategy for
treating malignancies [36, 37]. ER stress triggers un-
folded protein response (UPR) pathways, including the
IRE1 pathway, the PKR-like ER-resistant kinase pathway
and the activating transcription factor 6 pathway [38].
Data accumulated by us and others have revealed that
IR activates ER stress and UPR pathways through the in-
duction of DNA damage [24, 39]. Here, IRE1α and phos-
phorylated eIF2α, which are both UPR-related proteins,
increased in cells treated with combined YCW1 and IR
(Fig. 3a). Using TEM, the ultrastructures of the 4 T1
cells indicated ER stress after the treatment with com-
bined treatment (Fig. 4). Evidence indicating that ER
stress can induce cell death, including apoptosis and au-
tophagy, has been reported [40, 41]. We found that com-
bined treatment mainly induced autophagy and a small
amount of apoptosis in 4 T1 cells (Figs. 3, 4 and
Additional file 1: Figure S1). In our in vivo study, tumor
tissues from the mice treated with combined treatment
showed higher autopahgic levels compared with mice
treated with a single agent (Fig. 7d). However, the role of
autophagy in regulating cancer cell death or survival re-
mains controversial. Furthermore, an increase in autoph-
agic flux may be the a key factor that modulates
autophagy to cell death [29]. The present study shows
that Atg5 shRNA decreased combined treatment-
induced cytotoxicity (Fig. 5c). Additionally, the com-
bined treatment caused autophagic flux (Fig. 5d). There-
fore, our results showed that the combination treatment
with YCW1 and IR induced autophagic cell death in
TNBC cells.
Members of the Bcl-2 family are contained in multi-
protein complexes at the ER, where they regulate diverse
cellular processes including autophagy, calcium homeo-
stasis and the unfolded-protein response [42]. The Bcl-2
family comprises three subfamilies, an anti-apoptotic
family, a pro-apoptotic multi-domain family and a pro-
apoptotic BH3-only protein family [43]. Recent evidence
shows that this family affects not only apoptosis but also
autophagy [19, 44]. In the present study, Bcl-XL protein
expression decreased in 4 T1 cells following combined
treatment (Fig. 3a). Although BNIP3 is in the pro-
apoptotic BH3-only protein family, it was recently found
to increase resistance to apoptosis, and it was implicated
that BNIP3 may also play an important role in autoph-
agy [45, 46]. Moreover, growing evidence has shown that
the overexpression of BNIP3 can be detected in many
malignancies, such as glioma, breast cancer and prostate
cancer [14, 47]. In addition, BNIP3 was not identified in
normal breast but was up-regulated in breast cancer
[15]. Park et al. indicated that BNIP3 degradation was
triggered by autophagy and could be regulated by
mTORC1 and AMPK [48]. In this study, we found that
BNIP3 significantly decreased in cells or tumors follow-
ing combined treatment compared with those that re-
ceived YCW1 or IR alone (Figs. 6a and 7d). 4 T1 cells
transfected with BNIP3 shRNA showed a significant in-
crease the number of autophagic cells and reduced the
viability compared with the control shRNA (Fig. 6c and
d). Furthermore, the overexpression of BNIP3 decreased
autophagy (Fig. 6f ). Therefore, combined treatment in-
duced autophagic cell death through the inhibition of
BNIP3 in TNBC cells.
Conclusions
Taken together, these data suggest that the combination
of YCW1 and IR exerts a cytotoxic effect on TNBC cells
that is associated with increased levels of autophagy and
ER stress. More importantly, BNIP3 was degraded by
the combined treatment-induced autophagy. This com-
bination benefit was also observed in vivo using an
orthotopic breast cancer model. Our data show that
combining YCW1 and IR and targeting BNIP3 are
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therapeutic options that should be further investigated
for the treatment of TNBC.
Methods
Preparation of YCW1
The complete chemical name of YCW1 is octanedioic
acid [3-(2-(5-methoxy-1H-indol-1-yl)ethoxy)phenyl]-
amide N-hydroxyamide. Requests for this compound
should be sent to wjhuang@tmu.edu.tw.
Cell culture
The murine breast cancer cell line 4 T1 (ATCC CRL-
2539) and human breast cancer cell line MDA-MB-231
(ATCC HTB-26) were obtained from the American Type
Culture Collection (ATCC). The luciferase-expressing
murine breast cancer cell line 4 T1-Luc was obtained
from Dr. M.L. Kuo (Institute of Toxicology, National
Taiwan University, Taipei, Taiwan) [49]. The cells were
cultured in Dulbecco’s modified essential medium
(DMEM) (Gibco BRL, Grand Island, NY, USA) supple-
mented with an antibiotic containing 100 U/ml penicillin
and 100 μg/ml streptomycin (Gibco BRL, Grand Island,
NY, USA) and 10 % fetal bovine serum (HyClone, South
Logan, UT, USA). The cells were incubated in a humidified
atmosphere containing 5 % CO2 at 37 °C. Exponentially
growing cells were detached using 0.05 % trypsin-EDTA
(Gibco BRL, Grand Island, NY) in DMEM.
Irradiation treatment and cell viability assay
IR was performed with 6 MV X-rays using a linear accel-
erator (Digital M Mevatron Accelerator, Siemens Medical
Systems, CA, USA) at a dose rate of 5 Gy/min. An add-
itional 2 cm of a tissue-equivalent bolus was placed on the
top of the plastic tissue-culture flasks to ensure electronic
equilibrium, and 10 cm of a tissue-equivalent material was
placed under the flasks to achieve full backscatter. Cells
were immediately treated with YCW1 following IR treat-
ment. Next, the cells were centrifuged and resuspended in
0.1 ml PBS. Each cell suspension (0.02 ml) was mixed with
0.02 ml of a trypan blue solution (0.2 % in PBS). After 1 or
2 min, each solution was analyzed on a hemocytometer,
with blue-stained cells counted as nonviable.
Determination of early apoptosis
Apoptosis was assessed by quantifying the translocation
of phosphatidylserine to the cell surface, detected with
Annexin V staining (Calbiochem, San Diego, CA, USA).
Experiments were conducted according to our previous
reports [5, 50].
Immunofluorescence microscopy
The cells were cultured on coverslips. Cells were har-
vested and fixed in 4 % paraformaldehyde and blocked
with 1 % BSA for 30 min. This was followed by
incubation with a specific antibody against LC3 (MBL,
Japan) for 1 h. After washing, the cells were labeled with
a DyLight™ 488-conjugated affinipure goat anti-rabbit
IgG (Jackson Immuno-Research Laboratories, PA, USA)
for 1 h and with DAPI. Finally, the cells were washed in
PBS, covered with a coverslip, and examined with a
fluorescence microscope or confocal microscope (Carl
Zeiess LSM780, Instrument Development Center,
NCKU). To quantify the number of LC3 dots per cell, a
minimum of 50 cells per sample was counted.
Transmission electron microscopy (TEM)
Cells were trypsinized and harvested, then fixed for 1 h
in a solution containing 2.5 % glutaraldehyde and 2 %
paraformaldehyde in 0.1 M cacodylate buffer, pH 7.3.
After fixation, the samples were postfixed with buffer
containing 1 % OsO4 for 30 min. Ultra-thin sections
were subsequently observed under a transmission elec-
tron microscope (JEOL JEM-1200EX, Japan) at 100 kV.
Western blot analysis
Total cellular protein lysate was prepared by harvesting
cells in protein extraction buffer for 1 h at 4 °C, as de-
scribed previously [4]. GAPDH expression represented
the protein loading control. Anti-GAPDH, anti-BNIP3,
anti-IRE1α, phospho-eIF2α and anti-beclin 1 antibodies
were obtained from Abcam (Cambridge, MA, USA); anti-
LC3 and anti-eIF2α antibodies were obtained from
Abgent (San Diego, CA, USA); anti-acetyl-histone H3 and
acetyl-histone H4 antibodies were obtained from Millipore
(Bedford, MA, USA); anti-acetyl-tubulin antibody was ob-
tained from Sigma (St. Louis, Missouri, USA); anti-Bcl-XL
antibody was obtained from Cell Signaling Technology
(Ipswich, MA, USA); and anti-p62/SQSTM1 antibody was
obtained from MBL (Nagoya, Japan).
Transfection of shRNA and plasmids
We used Arrest-In Transfection Reagent (Thermo, MA,
USA) to transfect cells according to the manufacturer’s
protocol. RNAi reagents were obtained from the Na-
tional RNAi Core Facility located at the Institute of Mo-
lecular Biology/Genomic Research Center, Academia
Sinica, supported by the National Core Facility Program
for Biotechnology Grants of NSC (NSC 100-2319-B-
001-002). The mouse library is referred to as TRC-Mm
1.0. Individual clones are identified as shRNA
TRCN0000072184, shRNA TRCN0000009691, TRCN
0000099432, TRCN0000099433, TRCN0000375819 and
shRNA TRCN0000229458. BNIP3 plasmid was obtained
from OriGene Technologies Inc. (Rockville, MD, USA).
Orthotopic breast cancer model
All experiments on mice were performed according to the
guidelines of our institute (the Guide for Care and Use of
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Laboratory Animals, Medical College, National Cheng
Kung University). The animal use protocol listed below has
been reviewed and approved by the Institutional Animal
Care and Use Committee of National Cheng Kung Univer-
sity, Taiwan (Approval No: 104232). Six week-old female
Balb/c mice were acquired from the National Laboratory
Animal Center (Taiwan). The animals were housed five per
cage at 24 ± 2 °C and 50 % ± 10 % relative humidity and
subjected to a 12-h light/12-h dark cycle. 4 T1-Lluc cells
(5 × 104 cells in 0.2 ml of PBS) were injected into the lactif-
erous ducts of the 4th mammary fat pads in the female
Balb/c mice. The mice were randomized into four treat-
ment groups (5 mice per group): (1) Control (DMSO), (2)
25 mg/kg YCW1 three times per week for three weeks, (3)
a single dose of 4 Gy IR, or (4) a combination of treatments
with 25 mg/kg YCW1 three times per week and a single
dose of 4 Gy IR. Bioluminescence imaging was conducted
using an IVIS 200 imaging system coupled to a data acqui-
sition computer running Living Image Software (XENO-
GEN). Before imaging, the mice were anesthetized with
isoflurane and injected i.p with 150 mg/kg body weight
endotoxin-free luciferase substrate (VivoGlo™, Promega).
Body weights were measured once per week and used as an
indicator of the systemic toxicity of the treatment. There
were no deaths in any group during the experimental
period. Mice were sacrificed via CO2 exposure. After sacri-
ficing, the tumor tissues were formalin fixed and paraffin
embedded for immunohistochemistry.
Immunohistochemical (IHC) staining analysis
Paraffin-embedded tissue sections (4 μm) were dried,
deparaffinized, and rehydrated. Following microwave
pretreatment in citrate buffer (pH 6.0; for antigen re-
trieval), the slides were immersed in 3 % hydrogen per-
oxide for 20 min to block the activity of endogenous
peroxidases. After extensive washing with PBS, the slides
were incubated overnight at 4 °C with the anti-LC3
(MBL, Japan) or anti-BNIP3 (Abcam, MA, USA) anti-
body. The sections were then incubated with a second-
ary antibody for 1 h at room temperature, and the slides
were developed using the STARR TREK Universal HRP
detection kit (Biocare Medical, Concord, CA). Finally,
the slides were counterstained using hematoxylin. Each
slide was imaged at low magnification (×100).
Biochemistry tests
Whole blood samples from the treated mice were col-
lected by intracardiac puncture and centrifuged at
2000 × g for 20 min to separate the serum. The bio-
chemistry evaluation included assessing the glutamate
oxaloacetate transaminase (GOT) activity, glutamate
pyruvate transaminase (GPT) activity, albumin levels
and blood urea nitrogen (BUN) levels. All experiments
and procedures were performed in accordance with the
Institutional Care Use Committee guidelines.
Statistical analysis
Data are expressed as the mean ± SD. Statistical signifi-
cance was determined using Student’s t-test for compari-
sons between the means or one-way analysis of variance
with post-hoc Dunnett’s test [51]. Differences were con-
sidered significant when p < 0.05.
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